Gut microbial production of imidazole propionate drives Parkinson's pathologiesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers investigated whether specific gut microbes and their metabolites can directly cause Parkinson's disease pathology. They focused on Streptococcus mutans and its enzyme urocanate reductase (UrdA), which produces the metabolite imidazole propionate (ImP).
How was it studied?
The team reanalyzed metagenomic data from 491 Parkinson's patients and 234 healthy elderly controls, then measured plasma ImP in 65 patients versus 65 matched controls. In mice, they colonized germ-free animals with S. mutans or with Escherichia coli engineered to express UrdA, and separately injected ImP directly into the brain or gave it systemically, with and without the mTORC1 inhibitor rapamycin.
What did they find?
S. mutans and its urdA gene were more abundant in the PD gut microbiome, and plasma ImP was significantly elevated in PD patients. Gut colonization with S. mutans or UrdA-expressing E. coli raised brain ImP levels and caused dopaminergic neuron loss, astrogliosis, microgliosis, and motor impairment, and worsened alpha-synuclein aggregation from preformed fibrils. ImP alone reproduced these effects, and rapamycin blocked the mTORC1 activation and downstream pathology, while the p38gamma inhibitor pirfenidone blocked ImP-induced neurotoxicity in cultured neurons.
Why it matters
This identifies a specific gut bacterium and metabolite, ImP produced via UrdA, as a direct microbial driver of Parkinson's pathology through the mTORC1 pathway. It points to UrdA inhibition or mTORC1-targeted drugs as possible therapeutic strategies aimed at the gut-brain axis.